lower schreef op 28 januari 2015 23:12:
Salix to restate financials 2013 and 2014
• After an accounting review by the Board's Audit Committee, in consultation with others, Salix Pharmaceuticals (NASDAQ:SLXP) announces that its financial statements for 2013 and the first three quarters of 2014 contain errors and should no longer be relied upon. The errors are primarily related to the timing of the recognition of certain revenue, revenue-reducing returns and discounts and expense items.
• The corrections will reduce net product revenue and net income $20.1M and $11.8M ($0.18 per share), respectively, for 2013. For the first three quarters of 2014, net product revenues will be reduced by $0.7M with no change in net loss.
• Salix expects to file the revised statements with the SEC prior to filing its 10-K on or before March 2.
• Investors appear unconcerned. Shares are up 1% after hours on light volume.